Psychiatric drug development may be set to exit the doldrums, says Husseini Manji, head of neuroscience at Janssen. Manji, a former Director of the Mood and Anxiety Disorders Program at the US National Institute of Mental Health (NIMH), points to his company's recent launch of pivotal trials for esketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist that holds promise in treatment-resistant depression, as one of several programmes that could open up new biochemical space in psychiatric diseases. Anti-inflammatories and novel modulators of the endocannabinoid system are also on deck. The field is only a success or two away from a rebound, he tells Asher Mullard.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Husseini Manji. Nat Rev Drug Discov 14, 742–743 (2015). https://doi.org/10.1038/nrd4771
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4771
This article is cited by
-
Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant
Neuroscience Bulletin (2016)
